Maintenance Treatment of Renal Anemia in Dialysis Subjects (MIYABI HD-M)
A Randomized, Active-controlled, Double-blinded, Double-dummy, Parallel-group, Multicenter Study to Investigate the Efficacy and Safety of Oral Molidustat in Comparison to Darbepoetin Alfa in Dialysis Subjects Treated With Erythropoiesis-Stimulating Agents (ESAs)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Chiba, Japan, 263-0043
- Medical corporation association Shunshin-kai Inage hospital
-
Fukuoka, Japan, 810-0012
- Ikeda Vascular Access Nephrology Dialysis
-
Fukuoka, Japan, 815-0038
- Oohashi internal medicine circulatory Clinic
-
Kumamoto, Japan, 861-0135
- Ueki Imafuji Clinic
-
Nagano, Japan, 380-0904
- Medical Corporation Suzukihinyoukika
-
Nagasaki, Japan, 850-0032
- Nagasaki Kidney Hospital
-
Osaka, Japan, 543-0052
- Akagaki Clinic
-
Osaka, Japan, 552-0007
- Nishi Shinryosho
-
Osaka, Japan, 555-0001
- Chibune Clinic
-
Saitama, Japan, 339-0033
- Iwatsuki-minami Hospital
-
Yamagata, Japan, 990-0834
- Yamagata Tokushukai Hospital
-
-
Aichi
-
Nagoya, Aichi, Japan, 465-0025
- Hakuyoukai Medical corporation Hakuyoukai Hospital
-
-
Chiba
-
Kashiwa, Chiba, Japan, 277-0084
- Shinkashiwa Clinic
-
Kisarazu, Chiba, Japan, 292-0805
- Kisarazu Clinic
-
-
Ehime
-
Niihama, Ehime, Japan, 792-0812
- Kuwajima Clinic
-
-
Fukui
-
Sabae, Fukui, Japan, 916-0044
- Sabae kidney Clinic
-
-
Fukuoka
-
Kasuya-gun, Fukuoka, Japan, 811-0120
- Houshikai Kano hospital
-
Kitakyushu, Fukuoka, Japan, 805-0050
- Saiseikai Yahata General Hospital
-
-
Gunma
-
Midori, Gunma, Japan, 379-2311
- Sanshikai Toho Hospital
-
-
Hokkaido
-
Asahikawa, Hokkaido, Japan, 078-8211
- Asahikawa-Kosei General Hospital
-
Chitose, Hokkaido, Japan, 066-0062
- Koizumi Cardiology Medical Clinic
-
Ishikari, Hokkaido, Japan, 061-3213
- Ishikari Hospital
-
Noboribetsu, Hokkaido, Japan, 059-0026
- Itami Kidney Clinic
-
Sapporo, Hokkaido, Japan, 060-0008
- Souen Central Hospital
-
-
Ibaraki
-
Kasama, Ibaraki, Japan, 309-1793
- Ibaraki Prefectural Central Hospital
-
Koga, Ibaraki, Japan, 306-0014
- Japanese Red Cross Koga Hospital
-
Mito, Ibaraki, Japan, 310-0015
- Mito Kyodo General Hospital
-
Totte, Ibaraki, Japan, 302-0011
- Tokiwa Clinic
-
Tsuchiura, Ibaraki, Japan, 300-0062
- Tsuchiura Beryl Clinic
-
Tsukuba, Ibaraki, Japan, 305-0861
- Kikuchi Medical Clinic
-
-
Ishikawa
-
Hakusan, Ishikawa, Japan, 924-8588
- Public Central Hospital of Matto Ishikawa
-
-
Kagawa
-
Sakaide, Kagawa, Japan, 762-0007
- Kaisei Hospital
-
-
Kanagawa
-
Atsugi, Kanagawa, Japan, 243-0013
- Honatsugi Medical Clinic
-
Chigasaki, Kanagawa, Japan, 253-0052
- Chigasaki Central Clinic
-
Sagamihara, Kanagawa, Japan, 252-0385
- Toshiba Rinkan Hospital
-
Yokohama, Kanagawa, Japan, 224-0032
- Yokohama Jin Clinic
-
Yokohama, Kanagawa, Japan, 225-0015
- Eda Clinic
-
Yokohama, Kanagawa, Japan, 233-0013
- Kaminagaya Saitou Clinic
-
-
Miyagi
-
Kurokawa-gun, Miyagi, Japan, 981-3632
- Seisuikai Yoshioka Mahoroba Clinic
-
Osaki, Miyagi, Japan, 989-6117
- Eijinkai Hospital
-
-
Nagano
-
Iida, Nagano, Japan, 395-8505
- Iida Hospital
-
Matsumoto, Nagano, Japan, 390-0821
- Kanno Dialysis & Vascular Access Clinic
-
Matsumoto, Nagano, Japan, 390-1401
- Matsumoto City Hospital
-
Ueda, Nagano, Japan, 386-0405
- Maruko Central Hospital
-
-
Osaka
-
Hirakata, Osaka, Japan, 573-1195
- Arisawa General Hospital
-
Toyonaka, Osaka, Japan, 560-0004
- Toyonaka Keijinkai Clinic
-
-
Saitama
-
Hanyu, Saitama, Japan, 348-0045
- Hanyu General Hospital
-
Higashimatsuyama, Saitama, Japan, 355-0016
- Higashimatsuyamakohjin Clinic
-
Koshigaya, Saitama, Japan, 343-0823
- Saiyu Clinic
-
Toda, Saitama, Japan, 335-0023
- Todachuo General Hospital
-
-
Tokyo
-
Hachioji, Tokyo, Japan, 192-0082
- Hachioji Azumacho Clinic
-
Kodaira, Tokyo, Japan, 187-0001
- Kodaira Kitaguchi Clinic
-
-
Yamaguchi
-
Ube, Yamaguchi, Japan, 755-0155
- Saint Hill Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject with ESKD (end-stage kidney disease) on regular dialysis (including, hemodiafiltration, hemofiltration, hemodialysis, and other modalities except for peritoneal dialysis) weekly or more than weekly for at least 12 weeks prior to randomization
- Body weight (after dialysis) > 40 and ≤ 160 kg at screening
- Male or female subject ≥ 20 years of age at screening
- At least one kidney
- Treated with weekly or bi-weekly dose of darbepoetin alfa, monthly or bi-weekly dose of epoetin beta pegol, OR weekly, biweekly, twice or three times per week dose of epoetin alfa/beta, and having had no more than one dose change within 8 weeks prior to randomization
- Mean screening Hb level ≥ 9.5 and < 12.0 g/dL (mean of all central laboratory Hb levels before dialysis [at least 2 measurements must be taken ≥ 2 days apart] during the screening period, AND all Hb level must be measured by the central laboratory, AND the difference between the lowest level and highest level is < 1.2 g/dL), with the last screening Hb level measurement within 14 days prior to randomization
- Ferritin ≥ 100 ng/mL or transferrin saturation ≥ 20% at screening
- Serum folate level and serum vitamin B12 level above lower limit of normal (LLN) at screening
Exclusion Criteria:
- New York Heart Association (NYHA) Class III or IV congestive heart failure
- History of cardio- (cerebro-) vascular events (e.g., unstable angina, myocardial infarction, stroke, pulmonary thromboembolism, and acute limb ischemia) within 6 months prior to randomization
- Sustained, poorly controlled arterial hypertension (defined as systolic BP (blood pressure) ≥ 180mmHg or diastolic BP ≥ 110mmHg) or hypotension (defined as systolic BP < 90mmHg) at randomization
- Proliferative choroidal or retinal disease, such as neovascular agerelated macular degeneration or proliferative diabetic retinopathy requiring invasive treatment (e.g., intraocular injections or laser photocoagulation) at screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Molidustat group
Subjects in the molidustat group will receive molidustat and darbepoetin alfa placebo.
|
Starting dose of molidustat will be titrated based on the subject's Hb (Hemoglobin) response.
Administrated orally once daily (OD).
Matching placebo of Darbepoetin alfa.
|
|
Active Comparator: Darbepoetin alfa group
Subjects in the darbepoetin alfa group will receive molidustat placebo and darbepoetin alfa.
|
Starting dose of darbepoetin alfa will be titrated based on the subject's Hb (Hemoglobin) response.
Administrated weekly or once every two weeks by intravenous injection.
Matching placebo of Molidustat.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The mean Hb level during the evaluation period
Time Frame: From week 33 to 36
|
From week 33 to 36
|
|
The change in mean Hb level during the evaluation period from baseline
Time Frame: Baseline and week 33 to 36
|
Baseline and week 33 to 36
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Responder rate: proportion of responders among the subjects
Time Frame: From week 33 to 36
|
Responder is defined as meeting all of the following criteria: (i) Mean of the Hb levels in the target range (ii) ≥ 50% of the Hb levels in the target range (iii) No rescue treatment |
From week 33 to 36
|
|
Proportion of subjects who meet each component of the response
Time Frame: From week 33 to 36
|
Response: (i) Mean of the Hb levels in the target range (ii) ≥ 50% of the Hb levels in the target range (iii) No rescue treatment |
From week 33 to 36
|
|
Hb level
Time Frame: Up to 52 weeks
|
Up to 52 weeks
|
|
|
Change in Hb level
Time Frame: Baseline and up to 52 weeks
|
Baseline and up to 52 weeks
|
|
|
Proportion of subjects whose mean hemoglobin level is in the target range
Time Frame: From week 33 to 36
|
From week 33 to 36
|
|
|
Proportion of subjects whose mean hemoglobin level is above the target range
Time Frame: From week 33 to 36
|
From week 33 to 36
|
|
|
Proportion of subjects whose mean hemoglobin level is below the target range
Time Frame: From week 33 to 36
|
From week 33 to 36
|
|
|
Proportion of subjects with hemoglobin levels in the target range
Time Frame: Up to 52 weeks
|
Up to 52 weeks
|
|
|
Proportion of subjects with hemoglobin levels above the target range
Time Frame: Up to 52 weeks
|
Up to 52 weeks
|
|
|
Proportion of subjects with hemoglobin levels below the target range
Time Frame: Up to 52 weeks
|
Up to 52 weeks
|
|
|
Proportion of subjects whose maximum rise in Hb between each consecutive visits is above 0.5 g/dL/week
Time Frame: Up to 52 weeks
|
Defined as change in Hb level / duration between two visits (weeks)
|
Up to 52 weeks
|
|
Number of participants with serious adverse events
Time Frame: Up to 52 weeks
|
Up to 52 weeks
|
|
|
Maximum concentration (Cmax)
Time Frame: At baseline, week 8, week 24 and week 52
|
At baseline, week 8, week 24 and week 52
|
|
|
Area under the concentration-time curve (AUC)
Time Frame: At baseline, week 8, week 24 and week 52
|
At baseline, week 8, week 24 and week 52
|
|
|
EPO (Erythropoietin) serum concentration
Time Frame: At baseline, week 8, week 24 and week 52
|
At baseline, week 8, week 24 and week 52
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2.
- Akizawa T, Taguchi M, Matsuda Y, Iekushi K, Yamada T, Yamamoto H. Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies. BMJ Open. 2019 Jun 14;9(6):e026602. doi: 10.1136/bmjopen-2018-026602.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 19352
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.